AURA
Aura Biosciences, Inc.Company Information
- Company Name
- Aura Biosciences, Inc.
- CIK
- CIK0001501796
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- AURA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- AURA
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-05-16
- Last sale
- 2026-06-16
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 7,117,453
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 95,277,790
- Shares outstanding
- 94,863,400
- Ownership
- 100.44%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- -5.97%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 68 | 85 | 60 | 48 | 107 | 38 | 32 | 25 | 30 | 26 | 41 | 56 | ||||||
| Marketable Securities | 256 | 30 | 85 | 114 | 70 | 90 | 119 | 149 | 157 | 177 | 185 | 93 | ||||||
| Restricted Cash And Cash Equivalents At Carrying Value | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 5 | 4 | 5 | 8 | 7 | 7 | 10 | 9 | 8 | 9 | 6 | 5 | ||||||
| Assets Current | 329 | 119 | 150 | 170 | 184 | 135 | 161 | 183 | 196 | 212 | 232 | 154 | ||||||
| Restricted Cash And Cash Equivalents Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 15 | 15 | 16 | 16 | 17 | 17 | 17 | 18 | 18 | 19 | 19 | 20 | ||||||
| Other Assets Noncurrent | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | ||||||
| Property Plant And Equipment Net | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 5 | ||||||
| Assets | 348 | 138 | 169 | 190 | 204 | 155 | 183 | 205 | 218 | 235 | 255 | 180 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 2 | 3 | 2 | 2 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 1 | ||||||
| Operating Lease Liability Current | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Liabilities Current | 20 | 17 | 18 | 19 | 15 | 12 | 15 | 15 | 11 | 10 | 12 | 11 | ||||||
| Operating Lease Liability Noncurrent | 13 | 14 | 14 | 15 | 15 | 15 | 16 | 16 | 16 | 17 | 17 | 17 | ||||||
| Liabilities | 33 | 30 | 33 | 33 | 30 | 27 | 31 | 31 | 27 | 26 | 29 | 28 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Additional Paid In Capital | 915 | 622 | 617 | 611 | 603 | 530 | 526 | 522 | 519 | 516 | 513 | 417 | ||||||
| Treasury Stock Common Value | -39 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Retained Earnings Accumulated Deficit | -560 | -514 | -480 | -455 | -429 | -402 | -374 | -348 | -327 | -307 | -287 | -265 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -0 | -0 | 0 | 0 | 0 | 0 | 1 | -0 | 0 | 1 | -0 | ||||||
| Stockholders Equity | 315 | 107 | 137 | 157 | 175 | 128 | 152 | 175 | 191 | 209 | 226 | 152 | ||||||
| Liabilities And Stockholders Equity | 348 | 138 | 169 | 190 | 204 | 155 | 183 | 205 | 218 | 235 | 255 | 180 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | 103 | 64 | 64 | 63 | 62 | 50 | 50 | 50 | 50 | 50 | 49 | 38 | ||||||
| Shares Outstanding | 103 | 64 | 64 | 63 | 62 | 50 | 50 | 50 | 50 | 50 | 49 | 38 | ||||||
| Treasury Stock Common Shares | 7 | - | - | - | - | - | - | - | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAura Biosciences, Inc. (AURA) — SEC Financial Statements & Analysis
Aura Biosciences, Inc. (AURA) is a biological products, (no diagnostic substances) company, incorporated in DE. Aura Biosciences, Inc. trades on Nasdaq as: AURA. Aura Biosciences, Inc. (AURA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Aura Biosciences, Inc. carries a market cap of $673.53M, a P/E ratio of -5.14x, a P/B ratio of 2.14x, an enterprise value of $604.93M, and an EV/EBITDA multiple of -4.42x. On profitability, it posts a Return on Equity (ROE) of -53.49%, a Return on Assets (ROA) of -47.42%, and a Return on Invested Capital (ROIC) of -88.13%. Per share, it reports EPS of $-1.38, diluted EPS of $-1.38, free cash flow per share of $-1.09, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 29.23% year-over-year and EPS growth of -20.97% year-over-year. On the balance sheet, it maintains a current ratio of 16.82x, a quick ratio of 16.56x, working capital of $309.47M, a debt-to-equity ratio of 0.10x, a debt ratio of 0.09, free cash flow of $-103.35M (TTM), and net debt of $-68.60M. Figures sourced from SEC EDGAR.
- Market Cap
- $673.53M
- P/E TTM
- -5.14x
- EPS TTM
- $-1.38
- P/B TTM
- 2.14x
- ROE TTM
- -53.49%
- ROA TTM
- -47.42%
- Debt To Equity
- 0.10x
- Free Cash Flow TTM
- $-103.35M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Aura Biosciences, Inc. in?
Aura Biosciences, Inc. (AURA) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does AURA trade on?
Aura Biosciences, Inc. (AURA) trades on the Nasdaq.
Where is Aura Biosciences, Inc. incorporated?
Aura Biosciences, Inc. is incorporated in DE.
When was Aura Biosciences, Inc. (AURA)'s most recent SEC filing?
Aura Biosciences, Inc. (AURA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is AURA's market cap?
Aura Biosciences, Inc. (AURA) has a market capitalization of $673.53M as of 2026-06-30.
What is AURA's EPS (earnings per share)?
Aura Biosciences, Inc. (AURA)'s trailing twelve month EPS is $-1.38 as of 2026-06-30.
What is AURA's ROE (return on equity)?
Aura Biosciences, Inc. (AURA)'s trailing twelve month Return on Equity (ROE) is -53.49% as of 2026-06-30.
What is AURA's ROA (return on assets)?
Aura Biosciences, Inc. (AURA)'s trailing twelve month Return on Assets (ROA) is -47.42% as of 2026-06-30.
What is AURA's ROIC (return on invested capital)?
Aura Biosciences, Inc. (AURA)'s trailing twelve month Return on Invested Capital (ROIC) is -88.13% as of 2026-06-30.
What is AURA's EV/EBITDA?
Aura Biosciences, Inc. (AURA)'s trailing twelve month EV/EBITDA is -4.42x as of 2026-06-30.